Potentiation of E7 antisense RNA-induced antitumor immunity by co-delivery of IL-12 gene in HPV16 DNA-positive mouse tumor

Gene Therapy

Volumn 5, Issue 11, 1998, Pages 1462-1471

  He, Y K ^a   Lui, V W Y ^a   Baar, J ^a   Wang, L ^a   Shurin, M ^a   Almonte, C ^a   Watkins, S C ^a   Huang, L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antisense RNA; Cancer; Cytokine gene; Gene therapy; HPV

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY RNA; CYTOKINE; INTERLEUKIN 12; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DOWN REGULATION; GENE TARGETING; IMMUNOGENETICS; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR REGRESSION; WART VIRUS;

ANIMALIA; HUMAN PAPILLOMAVIRUS TYPES;

EID: 0031770195     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300769     Document Type: Article

References (28)

1. zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1996; 1288: F55-78.
2. Bosch, FX et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995; 87: 796-802.
3. Curcio LD, Bouffard DY, Scanion KJ. Oligonucleotides as modulators of cancer gene expression. Phamacol Ther 1997; 74: 317332.
4. Mukhopadhyay T, Roth JA. Antisense regulation of oncogenes in human cancer. Crit Rev Oncogen 1996; 7: 151-190.
5. He YK, Huang L. Growth inhibition of human papillomavirus 16 DNA-positive mouse tumor by antisense RNA transcribed from U6 promoter. Cancer Res 1997; 57: 3993-3999.
6. Aoki K et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997; 8: 1105-1113.
7. Brunda MJ et al. Interleukin-12: murine models of a potent antitumor agent. Ann NY Acad Sci 1996; 795: 266-274.
8. Parkinson DR. Interleukin-2 in cancer therapy. Semin Oncol 1988; 15 (Suppl. 6): 10-16.
9. Li S, Huang L. In vivo gene transfer via intravenous administration of carionic lipid-protamine-DNA (LPD) complexes. Gene Therapy 1997; 4: 891-900.
10. Mario PC et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 1996; 56: 2531-2534.
11. Rakhmilevich AL et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine rumors. Proc Natl Acad Sci USA 1996; 93: 6291-6296.
12. Trojan J et al. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin like growth factor I RNA. Science 1993; 259: 94-97.
13. Trojan J et al. Presence of MHC-1 and B-7 molecules in rat and human glioma cells expressing antisense IGF-I mRNA. Neurosci Lett 1996; 212: 9-12.
14. Resnicoff M et al. Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA. Cancer Immunol Immunother 1996; 42: 64-68.
15. Vile RG et al. Generation of an antitumor immune response in a non-immunogenic tumor: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoral cytokine expression. Int J Cancer 1997; 71: 267-274.
16. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 39: 86-89.
17. He YK et al. EGFR antisense RNA transcribed from the U6 promoter inhibits human squamous cell carcinoma growth in vivo. J Natl Cancer Inst 1998; 90: 1080-1087.
18. Tahara H et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54: 182-189.
19. Zitvogel L et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 1995; 155: 1393-1403.
20. Rakhmilevich AL et al. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther 1997; 8: 1303-1311.
21. Bramson JL et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996; 7: 1995-2002.
22. Tan J et al. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res 1996; 56: 3399-3403.
23. Nabel GJ et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 11307-11311.
24. MacGregor GR et al. Using of E. coli lacZ (β-galactosidase) as a reporter gene. In Murray EJ (ed). Methods in Molecular Biology, Vol. 7: Gene Transfer and Expression Protocols. Humana Press: Clifton, NJ, 1991, pp 217-235.
25. Chen SH et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995; 92: 2577-2581.
26. Ohno T et al. Combination gene transfer to potentiate tumor regression. Gene Therapy 1997; 4: 361-366.
27. Sorgi FL, Huang L. Large-scale production of DC-Chol liposomes by microfluidization. Int J Pharm 1996; 144: 131-139.
28. Marr RA et al. Tumor immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNFα. Gene Therapy 1997; 4: 1181-1188.